Japan CAR-T Cell Therapies Market Size, Share, and COVID-19 Impact Analysis, By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Others), By End-User (Medical, Athletic, Travel, Maternity, and Fashion), and Japan CAR-T Cell Therapies Market Insights, Industry Trend, Forecasts to 2035

Japan CAR-T Cell Therapies Market Insights Forecasts to 2035

• The Japan CAR-T Cell Therapies Market Size Was Estimated at USD 362.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 15.63% from 2025 to 2035
• The Japan CAR-T Cell Therapies Market Size is Expected to Reach USD 1790.55 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan CAR-T Cell Therapies Market Size is anticipated to Reach USD 1790.55 Million by 2035, Growing at a CAGR of 15.63% from 2025 to 2035. The Japan CAR-T cell therapies market is primarily driven by the rising incidence of hematological cancers, including leukemia and multiple myeloma, particularly among the aging population.

Market Overview

CAR-T (Chimeric Antigen Receptor T-cell) Therapy is a form of personalized immunotherapy that involves genetically modifying a patients T-cells to express receptors that specifically target cancer cells. Chimeric Antigen Receptor T-cell therapy, or CAR-T cell therapy, is a cutting-edge immunotherapy that is mostly used to treat cancer. It entails altering a patients T cells, an immune cell type, to express a chimeric antigen receptor (CAR), which enables the lymphocytes to identify and target particular cancer cells. Certain blood malignancies, including acute lymphoblastic leukemia (ALL) and several forms of lymphoma, have responded especially well to CAR-T cell therapy. In Japan, CAR-T therapies are gaining traction due to their curative potential and alignment with the countrys precision medicine initiatives.

Report Coverage

This research report categorizes the market for the Japan CAR-T cell therapies market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan CAR-T cell therapies market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan CAR-T cell therapies market.

Driving Factors

The market for CAR-T cell treatment is anticipated to expand rapidly in Japan due to the increased prevalence of hematological diseases such multiple myeloma, leukemia, and lymphoma. The incidence of these blood-related cancers has been gradually rising as Japans population ages, necessitating more sophisticated and potent treatment alternatives. For example, the International Agency for Research on Cancer reports that in 2022, there were approximately 6,988 new instances of multiple myeloma in Japan. It is anticipated that the figure would rise to 7,350 by 2025. Additionally, it is predicted that by 2030, there will be 7,535 cases of multiple myeloma in Japan. 

Restraining Factors

The market expansion of CAR-T cell treatment is severely impeded by its high cost, which restricts patient and healthcare system accessibility and affordability. The cost barrier limits the therapys market penetration and patient access, particularly in nations lacking extensive reimbursement structures. Despite its clinical usefulness, CAR-T cell therapys acceptance is limited by the lack of long-term cost-benefit data, which makes many insurers and healthcare providers hesitant to fund it.

Market Segmentation

The Japan CAR-T cell therapies market share is classified into indication and end-user.

• The acute lymphoblastic leukemia segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan CAR-T cell therapies market is segmented by indication into acute lymphoblastic leukemia, non-hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia, and others. Among these, the acute lymphoblastic leukemia segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. One of the main indications for CAR T cell treatment is acute lymphoblastic leukemia (ALL), especially in patients who are young adults and children. The market has grown significantly as a result of CAR T cell therapys efficacy in treating ALL because it provides patients who have tried all other treatments with a new, efficient therapeutic alternative.

• The hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan CAR-T cell therapies market is segmented by end-user into hospitals, cancer treatment centers, and others. Among these, the hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Hospitals are among the main end users of CAR T cell therapies because they can provide complete care, including the infrastructure and medical knowledge required to deliver these intricate treatments.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan CAR-T cell therapies market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Gilead Sciences, Inc.
• Bristol Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan CAR-T Cell Therapies Market based on the following segments:

Japan CAR-T Cell Therapies Market, By Indication

• Acute Lymphoblastic Leukemia
• Non-Hodgkin Lymphoma
• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Others

Japan CAR-T Cell Therapies Market, By End-User

• Medical
• Athletic
• Travel
• Maternity
• Fashion